Webinar: The Advantages and Versatility of Flow Cytometry in Clinical Development

It is clear that the therapeutic future lies in biomarkers through the development of immunotherapies and companion diagnostics. Among the techniques of biomarker analysis, there is Flow Cytometry, which allows for precise analysis of liquid samples, but not only that.

Validation test development for specific biomarkers is a prerequisite for a successful application in translational research, preclinical and clinical phases. The advantages and disadvantages of this technique, the samples, the conditions of use: Cerba Research will open the doors of its worldwide laboratories for an hour. To answer all your questions about one of the leading technique of analysis for the development of innovative treatments, our experts will share their knowledge and experience.

Speakers

Nithianandan Selliah, Ph.D. – Global Head of Flow Cytometry at Cerba Research

Nithianandan obtained his PhD in Immunology and started to work on HIV research. After more than 10 years of HIV research, he joined a biotech company to work on biomarker discovery for autoimmune diseases. His interest in Flow cytometry at the biotech led him to join global CRO to work on assay development and validation in Flow cytometry for global clinical trials. He joined Cerba Research to continue to work on his passion of Flow cytometry in clinical trials and takes on new challenges to build the best Flow cytometry service for the clients. He is working with exceptional scientific teams in the US and Belgium to bring on new assays for various therapeutic indications, including Immuno-oncology and autoimmune diseases.

Ishita Modi – Director, Scientific Customer Solutions at Cerba Research

A microbiologist by education, Ishita finished her studies at Gujarat University in India and moved on to starting her career in the United States. She has more than 15 years of experience in the clinical and diagnostic research industry. Her expertise is in building a strong foundation of clinical operations and clinical research with a commitment to meeting client’s scientific needs to help advance medicine. Ishita has worked at CRO/Central Lab as well as at some of the leading clinical diagnostic labs in the region. Her scientific expertise includes infectious diseases and genetics and gained extensive experience in microbiology, virology, and molecular biology. Ishita is a New York State certified Medical Technologist and also certified IRB (Institutional Review Board) professional. Her experience over the years has made her very strong in all aspects of clinical research and regulatory requirements. She has a passion for advancing science and making a difference in the future of healthcare.

The Complexity of Myeloid-Derived Suppressor Cells in Non-small Cell Lung Cancer: A Combinatorial Multiplex IHC and Flow Cytometry Approach

Two Platforms for Next Generation Biomarker Discovery

COVID-19 Testing at Cerba Research